Macro Finance
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC Business·October 2, 2026·1 min read
Eli Lilly and Novo are developing new amylin drugs as a second biological lever for treating obesity and diabetes, following the success of GLP-1 medications. Amylin targets different pathways to regulate appetite and blood sugar, potentially offering enhanced efficacy or alternative options for patients who do not respond well to GLP-1s.
Read at CNBC BusinessDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.